Inhibitory Molecules in Signal Transduction Pathways of Cardiac Hypertrophy.

DOI PubMed 被引用文献4件 参考文献176件
  • TAKANO Hiroyuki
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • ZOU Yunzeng
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • AKAZAWA Hiroshi
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • TOKO Haruhiro
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • MIZUKAMI Miho
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • HASEGAWA Hiroshi
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • ASAKAWA Masayuki
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • NAGAI Toshio
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
  • KOMURO Issei
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine

書誌事項

タイトル別名
  • <B>Inhibitory Molecules in Signal Transduction Pathways of Cardiac Hypertrophy</B>

この論文をさがす

抄録

Cardiac hypertrophy is induced by a variety of diseases, such as hypertension, valvular diseases, myocardial infarction, and endocrine disorders. Although cardiac hypertrophy may initially be a beneficial response that normalizes wall stress and maintains normal cardiac function, prolonged hypertrophy is a leading cause of heart failure and sudden death. A number of studies have elucidated molecules responsible for the development of cardiac hypertrophy, including the mitogen-activated protein (MAP) kinases pathway, Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, and calcium/calmodulin-dependent protein phosphatase calcineurin pathway. These molecules may be targets for therapies designed to prevent the progression of cardiac hypertrophy. Numerous studies have focused on characterization of the intracellular signal transduction molecules that promote cardiac hypertrophy in order to clarify the molecular mechanisms, but there have been only a few reports on the inhibitory regulators of hypertrophic response. Recently, several molecules have attracted much attention as endogenous inhibitory regulators of cardiac hypertrophy. Enhancement of these inhibitory regulators would also seem to be a potential approach for the pharmacological treatment of hypertrophy. In this review, we summarize the inhibitory molecules of cardiac hypertrophy. (Hypertens Res 2002; 25: 491-498)

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (176)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ